Current immunotherapy for demyelinating diseases.
Authors:
- Khurram BashirKBKhurram Bashir
- John N. WhitakerJWJohn N. Whitaker
- 1 May 2002
- journal article
- editorial
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 59 (5) , 726-731
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 2001
- Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyThe Lancet, 2001
- Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple SclerosisNew England Journal of Medicine, 2000
- The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-upBrain, 1998
- Current immunotherapy in multiple sclerosisImmunology & Cell Biology, 1998
- Clinically definite multiple sclerosis following optic neuritisAnnals of Neurology, 1997
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-upBrain, 1993
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983